Matricellular proteins in the trabecular meshwork: Review and update

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 6, 2014, Pages 447-463

  Chatterjee, Ayan ^a   Villarreal, Guadalupe ^a   Rhee, Douglas J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 8; GELATINASE B; MATRICELLULAR PROTEIN; MYOCILIN; OSTEONECTIN; OSTEOPONTIN; SOMATOMEDIN BINDING PROTEIN; TENASCIN; THROMBOSPONDIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; EYE PROTEIN;

ANGIOGENESIS; BONE DENSITY; CELL ADHESION; CORNEA EPITHELIUM; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; OBESITY; OPEN ANGLE GLAUCOMA; PHAGOCYTOSIS; PIGMENT EPITHELIUM; REVIEW; SEQUENCE HOMOLOGY; SMOOTH MUSCLE FIBER; TRABECULAR MESHWORK; ANIMAL; AQUEOUS HUMOR; METABOLISM; OPTIC NERVE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AQUEOUS HUMOR; EXTRACELLULAR MATRIX; EYE PROTEINS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OPTIC NERVE; TRABECULAR MESHWORK;

EID: 84903704869     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0013     Document Type: Review

References (293)

1. Bill, A. Editorial: the drainage of aqueous humor. Invest. Ophthalmol. 14:1-3, 1975.
2. Bill, A., and Phillips, C.I. Uveoscleral drainage of aqueous humour in human eyes. Exp. Eye Res. 12:275-281, 1971.
3. Grant, W.M. Further studies on facility of flow through the trabecular meshwork. AMA Arch. Ophthalmol. 60:523-533, 1958.
4. Maepea, O., and Bill, A. The pressures in the episcleral veins, schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure. Exp. Eye Res. 49:645-663, 1989.
5. Moses, R.A., Grodzki Jr., W.J., Etheridge, E.L., and Wilson, C.D. Schlemm's canal: the effect of intraocular pressure. Invest. Ophthalmol. Vis. Sci. 20:61-68, 1981.
6. Pederson, J.E., Gaasterland, D.E., and MacLellan, H.M. Uveoscleral aqueous outflow in the rhesus monkey: importance of uveal reabsorption. Invest. Ophthalmol. Vis. Sci. 16:1008-1017, 1977.
7. Seiler, T., and Wollensak, J. The resistance of the tra-becular meshwork to aqueous humor outflow. Graefes Arch. Clin. Exp. Ophthalmol. 223:88-91, 1985.
8. Holmberg, A. The fine structure of the inner wall of schlemm's canal. Arch. Ophthalmol. 62:956-958, 1959.
9. Holmberg, A. Schlemm's canal and the trabecular mesh-work: an electron microscopic study of the normal structure in man and monkey (cercopithecus aethiops). Doc. Ophthalmol. 19:339-373, 1965.
10. Inomata, H., Bill, A., and Smelser, G.K. Aqueous humor pathways through the trabecular meshwork and into schlemm's canal in the cynomolgus monkey (macaca irus). An electron microscopic study. Am. J. Ophthalmol. 73:760-789, 1972.
11. Lee, W.R., Grierson, I., and McMenamin, P.G. The morphological response of the primate outflow system to changes in pressure and flow. In: Lutjen-Drecholl E., ed. Basic Aspects of Glaucoma Research. Stuttgart: Schat-tauer Verlag; 1982.
12. Tripathi, R.C. Mechanism of the aqueous outflow across the trabecular wall of schlemm's canal. Exp. Eye Res. 11:116-121, 1971.
13. Epstein, D.L., Freddo, T.F., Bassett-Chu, S., Chung, M., and Karageuzian, L. Influence of ethacrynic acid on outflow facility in the monkey and calf eye. Invest. Oph-thalmol. Vis. Sci. 28:2067-2075, 1987.
14. Epstein, D.L., and Rohen, J.W. Morphology of the tra-becular meshwork and inner-wall endothelium after ca-tionized ferritin perfusion in the monkey eye. Invest. Ophthalmol. Vis. Sci. 32:160-171, 1991.
15. Erickson-Lamy, K., Schroeder, A., and Epstein, D.L. Ethacrynic acid induces reversible shape and cytoskeletal changes in cultured cells. Invest. Ophthalmol. Vis. Sci. 33:2631-2640, 1992.
16. Barany, E.H., and Scotchbrook, S. Influence of testicular hyaluronidase on the resistance to flow through the angle of the anterior chamber. Acta Physiol. Scand. 30:240-248, 1954.
17. Barany, E.H., and Woodin, A.M. Hyaluronic acid and hyaluronidase in the aqueous humour and the angle of the anterior chamber. Acta Physiol. Scand. 33:257-290, 1955.
18. Bradley, J.M., Vranka, J., Colvis, C.M., et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39:2649-2658, 1998.
19. Ethier, C.R., Kamm, R.D., Palaszewski, B.A., Johnson, M.C., and Richardson, T.M. Calculations of flow resistance in the juxtacanalicular meshwork. Invest. Ophthal-mol. Vis. Sci. 27:1741-1750, 1986.
20. Gum, G.G., Samuelson, D.A., and Gelatt, K.N. Effect of hyaluronidase on aqueous outflow resistance in normo-tensive and glaucomatous eyes of dogs. Am. J. Vet. Res. 53:767-770, 1992.
21. Knepper, P.A., Farbman, A.I., and Telser, A.G. Exogenous hyaluronidases and degradation of hyaluronic acid in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 25:286-293, 1984.
22. Pang, I.H., Fleenor, D.L., Hellberg, P.E., Stropki, K., McCartney, M.D., and Clark, A.F. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest. Oph-thalmol. Vis. Sci. 44:3502-3510, 2003.
23. Anthony, T.L., Lindsey, J.D., and Weinreb, R.N. Lata-noprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest. Ophthalmol. Vis. Sci. 43:3705-3711, 2002
24. el-Shabrawi, Y., Eckhardt, M., Berghold, A., et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye (Lond) 14:375-383, 2000.
25. Lindsey, J.D., Kashiwagi, K., Boyle, D., Kashiwagi, F., Firestein, G.S., and Weinreb, R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15:869-875, 1996.
26. Lutjen-Drecoll, E., and Tamm, E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp. Eye Res. 47:761-769, 1988.
27. Lutjen-Drecoll, E., and Tamm, E. The effects of ocular hypotensive doses of PGF2 alpha-isopropylester on anterior segment morphology. Prog. Clin. Biol. Res. 312:437-446, 1989.
28. Ocklind, A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp. Eye Res. 67:179-191, 1998.
29. Weinreb, R.N., Kashiwagi, K., Kashiwagi, F., Tsuka-hara, S., and Lindsey, J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 38:2772-2780, 1997.
30. Weinreb, R.N., and Lindsey, J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:716-722, 2002.
31. Toris, C.B., Zhan, G.L., Zhao, J., Camras, C.B., and Ya-blonski, M.E. Potential mechanism for the additivity of pilocarpine and latanoprost. Am. J. Ophthalmol. 131:722-728, 2001.
32. Nilsson, S.F., Drecoll, E., Lutjen-Drecoll, E., et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47:4042-4049, 2006.
33. Keller, K.E., Bradley, J.M., Vranka, J.A., and Acott, T.S. Segmental versican expression in the trabecular meshwork and involvement in outflow facility. Invest. Ophthalmol. Vis. Sci. 52:5049-5057, 2011.
34. Swaminathan, S.S., Oh, D.J., Kang, M.H., et al. Secreted protein acidic and rich in cysteine (SPARC)-null mice exhibit more uniform outflow. Invest. Ophthalmol. Vis. Sci. 54:2035-2047, 2013.
35. Sage, E.H., and Bornstein, P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J. Biol. Chem. 266:14831-14834, 1991.
36. Chiquet-Ehrismann, R. Tenascins, a growing family of extracellular matrix proteins. Experientia 51:853-862, 1995.
37. Brekken, R.A., Sullivan, M.M., Workman, G., et al. Expression and characterization of murine hevin (SC1), a member of the SPARC family of matricellular proteins. J. Histochem. Cytochem. 52:735-748, 2004.
38. Bornstein, P., and Sage, E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14:608-616, 2002.
39. Rhee, D.J., Haddadin, R.I., Kang, M.H., and Oh, D.J. Matricellular proteins in the trabecular meshwork. Exp. Eye Res. 88:694-703, 2009.
40. Termine, J.D., Kleinman, H.K., Whitson, S.W., Conn, K.M., McGarvey, M.L., and Martin, G.R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26:99-105, 1981.
41. Yan, Q., and Sage, E.H. SPARC, a matricellular glyco-protein with important biological functions. J. Histochem. Cytochem. 47:1495-1506, 1999.
42. Brekken, R.A., and Sage, E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19:816-827, 2001.
43. Sage, H., Vernon, R.B., Decker, J., Funk, S., and Iruela-Arispe, M.L. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J. His-tochem. Cytochem. 37:819-829, 1989.
44. Frizell, E., Liu, S.L., Abraham, A., et al. Expression of SPARC in normal and fibrotic livers. Hepatology 21:847-854, 1995.
45. Blazejewski, S., Le Bail, B., Boussarie, L., et al. Osteo-nectin (SPARC) expression in human liver and in cultured human liver myofibroblasts. Am. J. Pathol. 151:651-657, 1997.
46. Nakken, K.E., Nygard, S., Haaland, T., et al. Multiple inflammatory-, tissue remodelling-and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand. J. Gastroenterol. 42:1245-1255, 2007.
47. Pichler, R.H., Hugo, C., Shankland, S.J., et al. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int. 50:1978-1989, 1996.
48. Allanore, Y., Wipff, J., Kahan, A., and Boileau, C. Genetic basis for systemic sclerosis. Joint Bone Spine 74:577-583, 2007.
49. Delany, A.M., McMahon, D.J., Powell, J.S., Greenberg, D.A., and Kurland, E.S. Osteonectin/SPARC polymorphisms in caucasian men with idiopathic osteoporosis. Osteoporos. Int. 19:969-978, 2008.
50. Framson, P.E., and Sage, E.H. SPARC and tumor growth: where the seed meets the soil? J. Cell Biochem. 92:679-690, 2004.
51. Barker, T.H., Baneyx, G., Cardo-Vila, M., et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 280:36483-36493, 2005.
52. Barker, T.H., Framson, P., Puolakkainen, P.A., Reed, M., Funk, S.E., and Sage, E.H. Matricellular homologs in the foreign body response: hevin suppresses inflammation, but hevin and SPARC together diminish angiogenesis. Am. J. Pathol. 166:923-933, 2005.
53. Zhou, X., Tan, F.K., Guo, X., and Arnett, F.C. Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum. 54:2626-2631, 2006.
54. Zhou, X.D., Xiong, M.M., Tan, F.K., Guo, X.J., and Ar-nett, F.C. SPARC, an upstream regulator of connective tissue growth factor in response to transforming growth factor beta stimulation. Arthritis Rheum. 54:3885-3889, 2006.
55. Bassuk, J.A., Birkebak, T., Rothmier, J.D., et al. Disruption of the sparc locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp. Eye Res. 68:321-331, 1999.
56. Bradshaw, A.D., Reed, M.J., and Sage, E.H. SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 50:1-10, 2002.
57. Bradshaw, A.D., Graves, D.C., Motamed, K., and Sage, E.H. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc. Natl. Acad. Sci. U.S.A. 100:6045-6050, 2003.
58. Bradshaw, A.D., Puolakkainen, P., Dasgupta, J., Davidson, J.M., Wight, T.N., and Helene Sage, E. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J. Invest. Dermatol. 120:949-955, 2003.
59. Delany, A.M., Amling, M., Priemel, M., Howe, C., Baron, R., and Canalis, E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J. Clin. Invest. 105:915-923, 2000.
60. Norose, K., Clark, J.I., Syed, N.A., et al. SPARC deficiency leads to early-onset cataractogenesis. Invest. Oph-thalmol. Vis. Sci. 39:2674-2680, 1998.
61. Puolakkainen, P., Bradshaw, A.D., Kyriakides, T.R., et al. Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. Am. J. Pathol. 162:627-635, 2003.
62. Taneda, S., Pippin, J.W., Sage, E.H., et al. Amelioration of diabetic nephropathy in SPARC-null mice. J. Am. Soc. Nephrol. 14:968-980, 2003.
63. Gilles, C., Bassuk, J.A., Pulyaeva, H., Sage, E.H., Foidart, J.M., and Thompson, E.W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 58:5529-5536, 1998.
64. McClung, H.M., Thomas, S.L., Osenkowski, P., et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci. Lett. 419:172-177, 2007.
65. Shankavaram, U.T., DeWitt, D.L., Funk, S.E., Sage, E.H., and Wahl, L.M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell Physiol. 173:327-334, 1997.
66. Berryhill, B.L., Kane, B., Stramer, B.M., Fini, M.E., and Hassell, J.R. Increased SPARC accumulation during cor-neal repair. Exp. Eye Res. 77:85-92, 2003.
67. Kantorow, M., Huang, Q., Yang, X.J., et al. Increased expression of osteonectin/SPARC mRNA and protein in age-related human cataracts and spatial expression in the normal human lens. Mol. Vis. 6:24-29, 2000.
68. Yan, Q., Clark, J.I., and Sage, E.H. Expression and characterization of SPARC in human lens and in the aqueous and vitreous humors. Exp. Eye Res. 71:81-90, 2000.
69. Mishima, H., Hibino, T., Hara, H., Murakami, J., and Otori, T. SPARC from corneal epithelial cells modulates collagen contraction by keratocytes. Invest. Ophthalmol. Vis. Sci. 39:2547-2553, 1998.
70. Magee, R.M., Hagan, S., Hiscott, P.S., et al. Synthesis of osteonectin by human retinal pigment epithelial cells is modulated by cell density. Invest. Ophthalmol. Vis. Sci. 41:2707-2711, 2000.
71. Kantorow, M., Horwitz, J., and Carper, D. Up-regulation of osteonectin/SPARC in age-related cataractous human lens epithelia. Mol. Vis. 4:17, 1998.
72. Gilmour, D.T., Lyon, G.J., Carlton, M.B., et al. Mice deficient for the secreted glycoprotein SPARC/osteo-nectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. Embo J. 17:1860-1870, 1998.
73. Gilbert, R.E., Cox, A.J., Kelly, D.J., et al. Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect. Tissue Res. 40:295-303, 1999.
74. Rhee, D.J., Fariss, R.N., Brekken, R., Sage, E.H., and Russell, P. The matricellular protein SPARC is expressed in human trabecular meshwork. Exp. Eye Res. 77:601-607, 2003.
75. Tomarev, S.I., Wistow, G., Raymond, V., Dubois, S., and Malyukova, I. Gene expression profile of the human tra-becular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci. 44:2588-2596, 2003.
76. Vittal, V., Rose, A., Gregory, K.E., Kelley, M.J., and Acott, T.S. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching. Invest. Ophthalmol. Vis. Sci. 46:2857-2868, 2005.
77. Haddadin, R.I., Oh, D.J., Kang, M.H., et al. SPARC-null mice exhibit lower intraocular pressures. Invest. Oph-thalmol. Vis. Sci. 50:3771-3777, 2009.
78. Chatterjee, A., Oh, D.J., Kang, M.H., and Rhee, D.J. Central corneal thickness does not correlate with Tono-Lab-measured IOP in several mouse strains with single transgenic mutations of matricellular proteins. Exp. Eye Res. 115C:106-112, 2013.
79. Oh, D.J., Kang, M.H., Ooi, Y.H., Choi, K.R., Sage, E.H., and Rhee, D.J. Overexpression of SPARC in human tra-becular meshwork increases intraocular pressure and alters extracellular matrix. Invest. Ophthalmol. Vis. Sci. 54:3309-3319, 2013.
80. Villarreal, Jr., G., Oh, D.J., Kang, M.H., and Rhee, D.J. Coordinated regulation of extracellular matrix synthesis by the microRNA-29 family in the trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 52:3391-3397, 2011.
81. Luna, C., Li, G., Qiu, J., Epstein, D.L., and Gonzalez, P. Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol. Vis. 15:2488-2497, 2009.
82. Yu, A.L., Birke, K., Moriniere, J., and Welge-Lussen, U. TGF-{beta}2 induces senescence-associated changes in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 51:5718-5723, 2010.
83. Kang, M.H., Oh, D.J., Kang, J.H., and Rhee, D.J. Regulation of SPARC by transforming growth factor beta2 in human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 54:2523-2532, 2013.
84. Villarreal Jr., G., Chatterjee, A., Oh, S.S., Oh, D.J., and Rhee, D.J. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 55:1657-1665, 2014.
85. Chatterjee, A., Villarreal Jr., G., Oh, D.J., Kang, M.H., and Rhee, D.J. AMP-activated protein kinase regulates intraocular pressure, extracellular matrix, and cytoskeleton in trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 55:3127-3139, 2014.
86. Thomasy, S.M., Wood, J.A., Kass, P.H., Murphy, C.J., and Russell, P. Substratum stiffness and latrunculin B regulate matrix gene and protein expression in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 53:952-958, 2012.
87. Picht, G., Welge-Luessen, U., Grehn, F., and Lutjen-Drecoll, E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207, 2001.
88. Tripathi, R.C., Li, J., Chan, W.F., and Tripathi, B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 59:723-727, 1994.
89. Swaminathan, S.S., Oh, D.J., Kang, M.H., Shepard, A.R., Pang I, and Rhee, D.J. TGFb2-mediated ocular hypertension is attenuated in SPARC-null mice. IOVS (In press).
90. Tawara, A., Okada, Y., Kubota, T., et al. Immuno-histochemical localization of MYOC/TIGR protein in the trabecular tissue of normal and glaucomatous eyes. Curr. Eye Res. 21:934-943, 2000.
91. Peters, D.M., Herbert, K., Biddick, B., and Peterson, J.A. Myocilin binding to hep II domain of fibronectin inhibits cell spreading and incorporation of paxillin into focal adhesions. Exp. Cell Res. 303:218-228, 2005.
92. Wentz-Hunter, K., Shen, X., Okazaki, K., Tanihara, H., and Yue, B.Y. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp. Cell Res. 297:39-48, 2004.
93. Stone, E.M., Fingert, J.H., Alward, W.L., et al. Identification of a gene that causes primary open angle glaucoma. Science 275:668-670, 1997.
94. Aroca-Aguilar, J.D., Sanchez-Sanchez, F., Ghosh, S., Fernandez-Navarro, A., Coca-Prados, M., and Escribano, J. Interaction of recombinant myocilin with the ma-tricellular protein SPARC: functional implications. Invest. Ophthalmol. Vis. Sci. 52:179-189, 2011.
95. Aroca-Aguilar, J.D., Sanchez-Sanchez, F., Ghosh, S., Coca-Prados, M., and Escribano, J. Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227. J. Biol. Chem. 280:21043-21051, 2005.
96. Vollrath, D., and Liu, Y. Temperature sensitive secretion of mutant myocilins. Exp. Eye Res. 82:1030-1036, 2006.
97. Gobeil, S., Letartre, L., and Raymond, V. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and ol-factomedin homology domain is essential for extracellular adhesion and secretion. Exp. Eye Res. 82:1017-1029, 2006.
98. Perbal, B. CCN proteins: multifunctional signalling regulators. Lancet 363:62-64, 2004.
99. Leask, A., and Abraham, D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell. Sci. 119:4803-4810, 2006.
100. Holbourn, K.P., Acharya, K.R., and Perbal, B. The CCN family of proteins: structure-function relationships. Trends Biochem. Sci. 33:461-473, 2008.
101. Brigstock, D.R. The connective tissue growth factor/cys-teine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr. Rev. 20:189-206, 1999.
102. Ivkovic, S., Yoon, B.S., Popoff, S.N., et al. Connective tissue growth factor coordinates chondrogenesis and an-giogenesis during skeletal development. Development 130:2779-2791, 2003.
103. Chen, Y., Abraham, D.J., Shi-Wen, X., et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol. Biol. Cell 15:5635-5646, 2004.
104. Abreu, J.G., Ketpura, N.I., Reversade, B., and De Ro-bertis, E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4:599-604, 2002.
105. Esson, D.W., Neelakantan, A., Iyer, S.A., et al. Expression of connective tissue growth factor after glaucoma filtration surgery in a rabbit model. Invest. Ophthalmol. Vis. Sci. 45:485-491, 2004.
106. Wang, J.M., Hui, N., Fan, Y.Z., Xiong, L., and Sun, N.X. Filtering bleb area and intraocular pressure following subconjunctival injection of CTGF antibody after glaucoma filtration surgery in rabbits. Int. J. Ophthalmol. 4:480-483, 2011.
107. Ho, S.L., Dogar, G.F., Wang, J., et al. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br. J. Ophthalmol. 89:169-173, 2005.
108. Browne, J.G., Ho, S.L., Kane, R., et al. Connective tissue growth factor is increased in pseudoexfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 52:3660-3666, 2011.
109. Junglas, B., Yu, A.H., Welge-Lussen, U., Tamm, E.R., and Fuchshofer, R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp. Eye Res. 88:1065-1075, 2009.
110. Wallace, D.M., Clark, A.F., Lipson, K.E., Andrews, D., Crean, J.K., and O'Brien, C.J. Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells. Invest. Ophthalmol. Vis. Sci. 54:7836-7848, 2013.
111. Junglas, B., Kuespert, S., Seleem, A.A., et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am. J. Pathol. 180:2386-2403, 2012.
112. Iyer, P., Maddala, R., Pattabiraman, P.P., and Rao, P.V. Connective tissue growth factor-mediated upregulation of neuromedin U expression in trabecular meshwork cells and its role in homeostasis of aqueous humor outflow. Invest. Ophthalmol. Vis. Sci. 53:4952-4962, 2012.
113. Su, Y., Cheng, J., Liu, H., Wang, F., and Zhao, S. Ade-novirus conducted connective tissue growth factor on extracellular matrix in trabecular meshwork and its role on aqueous humor outflow facility. Mol. Biol. Rep. 40:6091-6096, 2013.
114. Fuchshofer, R., Kuespert, S., Junglas, B., and Tamm, E.R. The prostaglandin F analog fluprostenol attenuates the fi-brotic effects of connective tissue growth factor on human trabecular meshwork cells. J. Ocul. Pharmacol. Ther. 30:237-245, 2014.
115. Baenziger, N.L., Brodie, G.N., and Majerus, P.W. A thrombin-sensitive protein of human platelet membranes. Proc. Natl. Acad. Sci. U.S.A. 68:240-243, 1971.
116. Baenziger, N.L., Brodie, G.N., and Majerus, P.W. Isolation and properties of a thrombin-sensitive protein of human platelets. J. Biol. Chem. 247:2723-2731, 1972.
117. McPherson, J., Sage, H., and Bornstein, P. Isolation and characterization of a glycoprotein secreted by aortic en-dothelial cells in culture. apparent identity with platelet thrombospondin. J. Biol. Chem. 256:11330-11336, 1981.
118. Adams, J., and Lawler, J. Extracellular matrix: the thrombospondin family. Curr. Biol. 3:188-190, 1993.
119. Adams, J.C., and Lawler, J. The thrombospondins. Int. J. Biochem. Cell Biol. 36:961-968, 2004.
120. Adams, J.C., and Lawler, J. The thrombospondins. Cold Spring Harb Perspect. Biol. 3:a009712, 2011.
121. Hiscott, P., Paraoan, L., Choudhary, A., Ordonez, J.L., Al-Khaier, A., and Armstrong, D.J. Thrombospondin 1, thrombospondin 2 and the eye. Prog. Retin. Eye Res. 25:1-18, 2006.
122. Hankenson, K.D., Sweetwyne, M.T., Shitaye, H., and Posey, K.L. Thrombospondins and novel TSR-containing proteins, R-spondins, regulate bone formation and remodeling. Curr. Osteoporos Rep. 8:68-76, 2010.
123. Cingolani, O.H., Kirk, J.A., Seo, K., et al. Thrombospondin-4 is required for stretch-mediated contractility augmentation in cardiac muscle. Circ. Res. 109:1410-1414, 2011.
124. Kim, D.S., Li, K.W., Boroujerdi, A., et al. Thrombos-pondin-4 contributes to spinal sensitization and neuropathic pain states. J. Neurosci. 32:8977-8987, 2012.
125. Zeng, J., Kim, D., Li, K.W., et al. Thrombospondin-4 contributes to spinal cord injury-induced changes in no-ciception. Eur. J. Pain 17: 1458-1464, 2013.
126. Unger, S., and Hecht, J.T. Pseudoachondroplasia and multiple epiphyseal dysplasia: new etiologic developments. Am. J. Med. Genet. 106:244-250, 2001.
127. Posey, K.L., and Hecht, J.T. The role of cartilage oligo-meric matrix protein (COMP) in skeletal disease. Curr. Drug Targets 9:869-877, 2008.
128. Tseng, S., Reddi, A.H., and Di Cesare, P.E. Cartilage oligomeric matrix protein (COMP): a biomarker of arthritis. Biomark Insights 4:33-44, 2009.
129. Adams, J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 17:25-51, 2001.
130. Alford, A.I., and Hankenson, K.D. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 38:749-757, 2006.
131. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107:929-934, 2001.
132. Bein, K., and Simons, M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. regulation of metalloproteinase activity. J. Biol. Chem. 275:32167-32173, 2000.
133. Yang, Z., Strickland, D.K., and Bornstein, P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and throm-bospondin 2. J. Biol. Chem. 276:8403-8408, 2001.
134. Murphy-Ullrich, J.E., Schultz-Cherry, S., and Hook, M. Transforming growth factor-beta complexes with throm-bospondin. Mol. Biol. Cell 3:181-188, 1992.
135. Schultz-Cherry, S., and Murphy-Ullrich, J.E. Thrombos-pondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 122:923-932, 1993.
136. Cockburn, C.G., and Barnes, M.J. Characterization of thrombospondin binding to collagen (type I) fibres: role of collagen telopeptides. Matrix 11:168-176, 1991.
137. Galvin, N.J., Vance, P.M., Dixit, V.M., Fink, B., and Frazier, W.A. Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J. Cell Biol. 104:1413-1422, 1987.
138. Mumby, S.M., Raugi, G.J., and Bornstein, P. Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J. Cell Biol. 98:646-652, 1984.
139. Sipes, J.M., Guo, N., Negre, E., Vogel, T., Krutzsch, H.C., and Roberts, D.D. Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a pep-tide from the second type I repeat of thrombospondin. J. Cell Biol. 121:469-477, 1993.
140. Sweetwyne, M.T., and Murphy-Ullrich, J.E. Thrombos-pondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol. 31:178-186, 2012.
141. Penttinen, R.P., Kobayashi, S., and Bornstein, P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. U.S.A. 85:1105-1108, 1988.
142. Crawford, S.E., Stellmach, V., Murphy-Ullrich, J.E., et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170, 1998.
143. Fitchev, P.P., Wcislak, S.M., Lee, C., et al. Thrombos-pondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab. Invest. 90: 1078-1090, 2010.
144. Hankenson, K.D., Bain, S.D., Kyriakides, T.R., Smith, E.A., Goldstein, S.A., and Bornstein, P. Increased marrow-derived osteoprogenitor cells and endosteal bone formation in mice lacking thrombospondin 2. J. Bone Miner. Res. 15:851-862, 2000.
145. Kyriakides, T.R., Zhu, Y.H., Smith, L.T., et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fi-brillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 140:419-430, 1998.
146. Agah, A., Kyriakides, T.R., Lawler, J., and Bornstein, P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol. 161:831-839, 2002.
147. Christensen, A.E., Fiskerstrand, T., Knappskog, P.M., Boman, H., and Rodahl, E. A novel ADAMTSL4 mutation in autosomal recessive ectopia lentis et pupillae. Invest. Ophthalmol. Vis. Sci. 51:6369-6373, 2010.
148. Greene, V.B., Stoetzel, C., Pelletier, V., et al. Confirmation of ADAMTSL4 mutations for autosomal recessive isolated bilateral ectopia lentis. Ophthalmic Genet. 31:47-51, 2010.
149. Keller, K.E., Bradley, J.M., and Acott, T.S. Differential effects of ADAMTS-1,-4, and-5 in the trabecular mesh-work. Invest. Ophthalmol. Vis. Sci. 50:5769-5777, 2009.
150. Hiscott, P., Schlotzer-Schrehardt, U., and Naumann, G.O. Unexpected expression of thrombospondin 1 by corneal and iris fibroblasts in the pseudoexfoliation syndrome. Hum. Pathol. 27:1255-1258, 1996.
151. Wang, S., Neekhra, A., Albert, D.M., Sorenson, C.M., and Sheibani, N. Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility. Arch. Ophthalmol. 130:336-341, 2012.
152. Flugel-Koch, C., Ohlmann, A., Fuchshofer, R., Welge-Lussen, U., and Tamm, E.R. Thrombospondin-1 in the trabecular meshwork: localization in normal and glauco-matous eyes, and induction by TGF-beta1 and dexa-methasone in vitro. Exp. Eye Res. 79:649-663, 2004.
153. Fleenor, D.L., Shepard, A.R., Hellberg, P.E., Jacobson, N., Pang, I.H., and Clark, A.F. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 47:226-234, 2006.
154. Fuchshofer, R., Yu, A.H., Welge-Lussen, U., and Tamm, E.R. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular mesh-work cells. Invest. Ophthalmol. Vis. Sci. 48:715-726, 2007.
155. Fuchshofer, R., Welge-Lussen, U., and Lutjen-Drecoll, E. The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system. Exp. Eye Res. 77:757-765, 2003.
156. Gottanka, J., Chan, D., Eichhorn, M., Lutjen-Drecoll, E., and Ethier, C.R. Effects of TGF-beta2 in perfused human eyes. Invest. Ophthalmol. Vis. Sci. 45:153-158, 2004.
157. Ochiai, Y., and Ochiai, H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 46:249-253, 2002.
158. Zhao, X., Ramsey, K.E., Stephan, D.A., and Russell, P. Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest. Ophthalmol. Vis. Sci. 45:4023-4034, 2004.
159. Haddadin, R.I., Oh, D.J., Kang, M.H., et al. Thrombos-pondin-1 (TSP1)-null and TSP2-null mice exhibit lower intraocular pressures. Invest. Ophthalmol. Vis. Sci. 53:6708-6717, 2012.
160. Bourdon, M.A., Wikstrand, C.J., Furthmayr, H., Matthews, T.J., and Bigner, D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43:2796-2805, 1983.
161. Chiquet, M., and Fambrough, D.M. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J. Cell Biol. 98:1937-1946, 1984.
162. Chiquet-Ehrismann, R., and Chiquet, M. Tenascins: regulation and putative functions during pathological stress. J. Pathol. 200:488-499, 2003.
163. Jakovcevski, I., Miljkovic, D., Schachner, M., and Andjus, P.R. Tenascins and inflammation in disorders of the nervous system. Amino Acids 44:1115-1127, 2013.
164. Brellier, F., Martina, E., Chiquet, M., et al. The adhesion modulating properties of tenascin-W. Int. J. Biol. Sci. 8:187-194, 2012.
165. Grogan, S.P., Chen, X., Sovani, S., et al. Influence of cartilage extracellular matrix molecules on cell phenotype and neocartilage formation. Tissue Eng. Part A 20: 264-274, 2013.
166. Katoh, D., Nagaharu, K., Shimojo, N., et al. Binding of alphavbeta1 and alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis 2:e65, 2013.
167. Brosicke, N., van Landeghem, F.K., Scheffler, B., and Faissner, A. Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels. Cell Tissue Res. 354:409-430, 2013.
168. Orend, G., and Chiquet-Ehrismann, R. Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp. Cell Res. 261:104-110, 2000.
169. Chiquet-Ehrismann, R., Kalla, P., Pearson, C.A., Beck, K., and Chiquet, M. Tenascin interferes with fibronectin action. Cell 53:383-390, 1988.
170. De Laporte, L., Rice, J.J., Tortelli, F., and Hubbell, J.A. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS One 8:e62076, 2013.
171. Feugate, J.E., Wong, L., Li, Q.J., and Martins-Green, M. The CXC chemokine cCAF stimulates precocious deposition of ECM molecules by wound fibroblasts, accelerating development of granulation tissue. BMC Cell Biol. 3:13, 2002.
172. Hou, Y., Lin, H., Zhu, L., et al. LPS increases the incidence of collagen-induced arthritis in mice through induction of protease HTRA1 expression. Arthritis Rheum. 65:2835-2846, 2013.
173. Makhluf, H.A., Stepniakowska, J., Hoffman, S., Smith, E., LeRoy, E.C., and Trojanowska, M. IL-4 upregulates te-nascin synthesis in scleroderma and healthy skin fibro-blasts. J. Invest. Dermatol. 107:856-859, 1996.
174. Pearson, C.A., Pearson, D., Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismann, R. Tenascin: CDNA cloning and induction by TGF-beta. Embo J. 7:2977-2982, 1988.
175. Fitch, P.M., Howie, S.E., and Wallace, W.A. Oxidative damage and TGF-beta differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease. Int. J. Exp. Pathol. 92:8-17, 2011.
176. Chablais, F., and Jazwinska, A. The regenerative capacity of the zebrafish heart is dependent on TGFbeta signaling. Development 139:1921-1930, 2012.
177. Fluck, M., Chiquet, M., Schmutz, S., Mayet-Sornay, M.H., and Desplanches, D. Reloading of atrophied rat soleus muscle induces tenascin-C expression around damaged muscle fibers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:R792-R801, 2003.
178. Jarvinen, T.A., Jozsa, L., Kannus, P., et al. Mechanical loading regulates tenascin-C expression in the osteotendi-nous junction. J. Cell Sci. 112 Pt 18:3157-3166, 1999.
179. Mercer, S., Odelberg, S.J., and Simon, H.G. A dynamic spatiotemporal extracellular matrix facilitates epicardial-mediated vertebrate heart regeneration. Dev. Biol. 382: 457-469, 2013.
180. Franz, M., Berndt, A., Neri, D., et al. Matrix metallo-proteinase-9, tissue inhibitor of metalloproteinase-1, B tenascin-C and ED-A fibronectin in dilated cardiomyop-athy: potential impact on disease progression and patients' prognosis. Int. J. Cardiol. 168:5344-5351, 2013.
181. Forsberg, E., Hirsch, E., Frohlich, L., et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. U.S.A. 93:6594-6599, 1996.
182. Fukamauchi, F., Mataga, N., Wang, Y.J., Sato, S., Youshiki, A., and Kusakabe, M. Abnormal behavior and neurotransmissions of tenascin gene knockout mouse. Biochem. Biophys. Res. Commun. 221:151-156, 1996.
183. Mackie, E.J., and Tucker, R.P. The tenascin-C knockout revisited. J. Cell. Sci. 112:3847-3853, 1999.
184. Matsuda, A., Yoshiki, A., Tagawa, Y., Matsuda, H., and Kusakabe, M. Corneal wound healing in tenascin knockout mouse. Invest. Ophthalmol. Vis. Sci. 40:1071-1080, 1999.
185. Jaggi, G.P., Laeng, H.R., Muntener, M., and Killer, H.E. The anatomy of the muscle insertion (scleromuscular junction) of the lateral and medial rectus muscle in humans. Invest. Ophthalmol. Vis. Sci. 46:2258-2263, 2005.
186. Ueda, J., Wentz-Hunter, K., and Yue, B.Y. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest. Ophthalmol. Vis. Sci. 43:1068-1076, 2002.
187. Yeung, A.M., Schlotzer-Schrehardt, U., Kulkarni, B., Tint, N.L., Hopkinson, A., and Dua, H.S. Limbal epithelial crypt: a model for corneal epithelial maintenance and novel lim-bal regional variations. Arch. Ophthalmol. 126:665-669, 2008.
188. Spurlin, 3rd, J.W., and Lwigale, P. Wounded embryonic corneas exhibit non-fibrotic regeneration and complete innervation. Invest. Ophthalmol. Vis. Sci. 54:6334-6344, 2013.
189. Mitamura, Y., Takeuchi, S., Ohtsuka, K., Matsuda, A., Hiraiwa, N., and Kusakabe, M. Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 25:1899, 2002.
190. Mitamura, Y., Takeuchi, S., Ohtsuka, K., et al. Tenascin-C levels in the vitreous of patients with proliferative vi-treoretinopathy. Ophthalmologica 217:422-425, 2003.
191. Palenski, T.L., Sorenson, C.M., and Sheibani, N. Inflammatory cytokine-specific alterations in retinal endo-thelial cell function. Microvasc. Res. 89:57-69, 2013.
192. Johnson, E.C., Jia, L., Cepurna, W.O., Doser, T.A., and Morrison, J.C. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 48:3161-3177, 2007.
193. Keller, K.E., Bradley, J.M., Kelley, M.J., and Acott, T.S. Effects of modifiers of glycosaminoglycan biosynthesis on outflow facility in perfusion culture. Invest. Ophthalmol. Vis. Sci. 49:2495-2505, 2008.
194. Keller, K.E., Kelley, M.J., and Acott, T.S. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest. Oph-thalmol. Vis. Sci. 48:1164-1172, 2007.
195. Pattabiraman, P.P., and Rao, P.V. Mechanistic basis of rho GTPase-induced extracellular matrix synthesis in trabec-ular meshwork cells. Am. J. Physiol. Cell. Physiol. 298:C749-C763, 2010.
196. Keller, K.E., Vranka, J.A., Haddadin, R.I., et al. The effects of tenascin C knockdown on trabecular meshwork outflow resistance. Invest. Ophthalmol. Vis. Sci. 54:5613-5623, 2013.
197. Matsumoto, K., Saga, Y., Ikemura, T., Sakakura, T., and Chiquet-Ehrismann, R. The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. J. Cell Biol. 125:483-493, 1994.
198. Burch, G.H., Gong, Y., Liu, W., et al. Tenascin-X deficiency is associated with ehlers-danlos syndrome. Nat. Genet. 17:104-108, 1997.
199. Schalkwijk, J., Zweers, M.C., Steijlen, P.M., et al. A recessive form of the ehlers-danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med. 345:1167-1175, 2001.
200. Penisson-Besnier, I., Allamand, V., Beurrier, P., et al. Compound heterozygous mutations of the TNXB gene cause primary myopathy. Neuromuscul. Disord. 23:664-669, 2013.
201. Merke, D.P., Chen, W., Morissette, R., et al. Tenascin-X haploinsufficiency associated with ehlers-danlos syndrome in patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 98:E379-E387, 2013.
202. Lethias, C., Elefteriou, F., Parsiegla, G., Exposito, J.Y., and Garrone, R. Identification and characterization of a conformational heparin-binding site involving two fibro-nectin type III modules of bovine tenascin-X. J. Biol. Chem. 276:16432-16438, 2001.
203. Margaron, Y., Bostan, L., Exposito, J.Y., et al. Tenascin-X increases the stiffness of collagen gels without affecting fibrillogenesis. Biophys. Chem. 147:87-91, 2010.
204. Mao, J.R., Taylor, G., Dean, W.B., et al. Tenascin-X deficiency mimics ehlers-danlos syndrome in mice through alteration of collagen deposition. Nat. Genet. 30:421-425, 2002.
205. Voermans, N.C., Verrijp, K., Eshuis, L., et al. Mild muscular features in tenascin-X knockout mice, a model of ehlers-danlos syndrome. Connect. Tissue Res. 52:422-432, 2011.
206. Elefteriou, F., Exposito, J.Y., Garrone, R., and Lethias, C. Binding of tenascin-X to decorin. FEBS Lett. 495:44-47, 2001.
207. Tuori, A., Uusitalo, H., Thornell, L.E., Yoshida, T., and Virtanen, I. The expression of tenascin-X in developing and adult rat and human eye. Histochem. J. 31:245-252, 1999.
208. Cipriani, V., Leung, H.T., Plagnol, V., et al. Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3. Hum. Mol. Genet. 21:4138-4150, 2012.
209. Tanihara, H., Ohira, A., Takahashi, M., Honda, Y., and Suzuki, S. Localization and possible gene expression of proteoglycan decorin in the trabecular meshwork. Curr. Eye Res. 14:727-730, 1995.
210. Ueda, J., and Yue, B.Y. Distribution of myocilin and extracellular matrix components in the corneoscleral meshwork of human eyes. Invest. Ophthalmol. Vis. Sci. 44:4772-4779, 2003.
211. Wirtz, M.K., Bradley, J.M., Xu, H., et al. Proteoglycan expression by human trabecular meshworks. Curr. Eye Res. 16:412-421, 1997.
212. Johnston, I.G., Paladino, T., Gurd, J.W., and Brown, I.R. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteo-nectin/BM40/SPARC. Neuron 4:165-176, 1990.
213. Nelson, P.S., Plymate, S.R., Wang, K., et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res. 58: 232-236, 1998.
214. Girard, J.P., and Springer, T.A. Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J. Biol. Chem. 271:4511-4517, 1996.
215. Hambrock, H.O., Nitsche, D.P., Hansen, U., et al. SC1/hevin. an extracellular calcium-modulated protein that binds collagen I. J. Biol. Chem. 278:11351-11358, 2003.
216. Sullivan, M.M., Barker, T.H., Funk, S.E., et al. Ma-tricellular hevin regulates decorin production and collagen assembly. J. Biol. Chem. 281:27621-27632, 2006.
217. Soderling, J.A., Reed, M.J., Corsa, A., and Sage, E.H. Cloning and expression of murine SC1, a gene product homologous to SPARC. J. Histochem. Cytochem. 45:823-835, 1997.
218. Li, Y., Aroca-Aguilar, J.D., Ghosh, S., Sanchez-Sanchez, F., Escribano, J., and Coca-Prados, M. Interaction of myocilin with the C-terminal region of hevin. Biochem. Biophys. Res. Commun. 339:797-804, 2006.
219. Graul, T.A., Kwon, Y.H., Zimmerman, M.B., et al. A case-control comparison of the clinical characteristics of glaucoma and ocular hypertensive patients with and without the myocilin Gln368Stop mutation. Am. J. Oph-thalmol. 134:884-890, 2002.
220. Kang, M.H., Oh, D.J., and Rhee, D.J. Effect of hevin deletion in mice and characterization in trabecular mesh-work. Invest. Ophthalmol. Vis. Sci. 52:2187-2193, 2011.
221. Senger, D.R., Wirth, D.F., and Hynes, R.O. Transformed mammalian cells secrete specific proteins and phospho-proteins. Cell 16:885-893, 1979.
222. Oldberg, A., Franzen, A., and Heinegard, D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an arg-gly-asp cell-binding sequence. Proc. Natl. Acad. Sci. U.S.A. 83:8819-8823, 1986.
223. Sodek, J., Ganss, B., and McKee, M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 11:279-303, 2000.
224. Denhardt, D.T., and Guo, X. Osteopontin: a protein with diverse functions. Faseb J. 7:1475-1482, 1993.
225. O'Regan, A., and Berman, J.S. Osteopontin: a key cyto-kine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81:373-390, 2000.
226. Nishimichi, N., Hayashita-Kinoh, H., Chen, C., Matsuda, H., Sheppard, D., and Yokosaki, Y. Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. J. Biol. Chem. 286:11170-11178, 2011.
227. Wolak, T., Sion-Vardi, N., Novack, V., et al. N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am. J. Hypertens. 26:326-333, 2013.
228. Sodek, J., Batista Da Silva, A.P., and Zohar, R. Osteopontin and mucosal protection. J. Dent. Res. 85:404-415, 2006.
229. Giachelli, C.M., and Steitz, S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19:615-622, 2000.
230. Liaw, L., Birk, D.E., Ballas, C.B., Whitsitt, J.S., Davidson, J.M., and Hogan, B.L. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101:1468-1478, 1998.
231. Rittling, S.R., and Denhardt, D.T. Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp. Nephrol. 7:103-113, 1999.
232. Yoshitake, H., Rittling, S.R., Denhardt, D.T., and Noda, M. Osteopontin-deficient mice are resistant to ovariecto-my-induced bone resorption. Proc. Natl. Acad. Sci. U.S.A. 96:8156-8160, 1999.
233. Nagao, M., Feinstein, T.N., Ezura, Y., et al. Sympathetic control of bone mass regulated by osteopontin. Proc. Natl. Acad. Sci. U.S.A. 108:17767-17772, 2011.
234. Morishita, M., Ono, N., Miyai, K., et al. Osteopontin deficiency enhances parathyroid hormone/parathyroid hormone related peptide receptor (PPR) signaling-induced alteration in tooth formation and odontoblastic morphology. Tissue Cell 43:196-200, 2011.
235. Shimizu, S., Okuda, N., Kato, N., et al. Osteopontin deficiency impairs wear debris-induced osteolysis via regulation of cytokine secretion from murine macrophages. Arthritis Rheum. 62:1329-1337, 2010.
236. Kase, S., Yokoi, M., Saito, W., et al. Increased osteo-pontin levels in the vitreous of patients with diabetic ret-inopathy. Ophthalmic Res. 39:143-147, 2007.
237. Miyazaki, K., Okada, Y., Yamanaka, O., et al. Corneal wound healing in an osteopontin-deficient mouse. Invest. Ophthalmol. Vis. Sci. 49:1367-1375, 2008.
238. Saika, S., Miyamoto, T., Ishida, I., Ohnishi, Y., and Ooshima, A. Osteopontin: a component of matrix in capsular opacification and subcapsular cataract. Invest. Ophthalmol. Vis. Sci. 44:1622-1628, 2003.
239. Saika, S., Sumioka, T., Okada, Y., et al. Wakayama symposium: modulation of wound healing response in the corneal stroma by osteopontin and tenascin-C. Ocul. Surf. 11:12-15, 2013.
240. Fujita, N., Fujita, S., Ogata, N., et al. Endogenous os-teopontin involvement in laser-induced choroidal neo-vascularization in mice. Invest. Ophthalmol. Vis. Sci. 52:9310-9315, 2011.
241. Abu El-Asrar, A.M., Imtiaz Nawaz, M., Kangave, D., Siddiquei, M.M., and Geboes, K. Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators Inflamm. 2012:493043, 2012.
242. Deeg, C.A., Eberhardt, C., Hofmaier, F., Amann, B., and Hauck, S.M. Osteopontin and fibronectin levels are decreased in vitreous of autoimmune uveitis and retinal expression of both proteins indicates ECM re-modeling. PLoS One 6:e27674, 2011.
243. Keller, K.E., Aga, M., Bradley, J.M., Kelley, M.J., and Acott, T.S. Extracellular matrix turnover and outflow resistance. Exp. Eye Res. 88:676-682, 2009.
244. Taube, A.B., Hardenborg, E., Wetterhall, M., et al. Proteins in aqueous humor from cataract patients with and without pseudoexfoliation syndrome. Eur. J. Mass. Spectrom. (Chichester, Eng) 18:531-541, 2012.
245. Birke, M.T., Neumann, C., Birke, K., Kremers, J., and Scholz, M. Changes of osteopontin in the aqueous humor of the DBA2/J glaucoma model correlated with optic nerve and RGC degenerations. Invest. Ophthalmol. Vis. Sci. 51:5759-5767, 2010.
246. Chowdhury, U.R., Jea, S.Y., Oh, D.J., Rhee, D.J., and Fautsch, M.P. Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye. Invest. Ophthalmol. Vis. Sci. 52:6443-6451, 2011.
247. Gabius, H.J. Animal lectins. Eur. J. Biochem. 243:543-576, 1997.
248. von der Lieth, C., Siebert, H., Kozar, T., et al. Lectin ligands: new insights into their conformations and their dynamic behavior and the discovery of conformer selection by lectins. Acta Anat. (Basel) 161:91-109, 1998.
249. Elola, M.T., Wolfenstein-Todel, C., Troncoso, M.F., Vasta, G.R., and Rabinovich, G.A. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol. Life Sci. 64:1679-1700, 2007.
250. Rabinovich, G.A., Riera, C.M., Landa, C.A., and Soto-mayor, C.E. Galectins: a key intersection between gly-cobiology and immunology. Braz. J. Med. Biol. Res. 32:383-393, 1999.
251. Zick, Y., Eisenstein, M., Goren, R.A., Hadari, Y.R., Levy, Y., and Ronen, D. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj. J. 19:517-526, 2004.
252. Poirier, F., and Robertson, E.J. Normal development of mice carrying a null mutation in the gene encoding the L14 S-type lectin. Development 119:1229-1236, 1993.
253. Colnot, C., Fowlis, D., Ripoche, M.A., Bouchaert, I., and Poirier, F. Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev. Dyn. 211:306-313, 1998.
254. Gruson, D., and Ko, G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin. Biochem. 45:719-726, 2012.
255. Baum, L.G., Seilhamer, J.J., Pang, M., Levine, W.B., Beynon, D., and Berliner, J.A. Synthesis of an en-dogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj. J. 12:63-68, 1995.
256. Perillo, N.L., Marcus, M.E., and Baum, L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. (Berl) 76:402-412, 1998.
257. Ozeki, Y., Matsui, T., Yamamoto, Y., Funahashi, M., Hamako, J., and Titani, K. Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 5:255-261, 1995.
258. Zhou, Q., and Cummings, R.D. The S-type lectin from calf heart tissue binds selectively to the carbohydrate chains of laminin. Arch. Biochem. Biophys. 281:27-35, 1990.
259. van den Brule, F.A., Buicu, C., Baldet, M., et al. Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem. Biophys. Res. Commun. 209:760-767, 1995.
260. Adams, L., Scott, G.K., and Weinberg, C.S. Biphasic modulation of cell growth by recombinant human ga-lectin-1. Biochim. Biophys. Acta 1312:137-144, 1996.
261. Scott, K., and Weinberg, C. Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj. J. 19:467-477, 2004.
262. Vasta, G.R., Ahmed, H., Bianchet, M.A., Fernandez-Robledo, J.A., and Amzel, L.M. Diversity in recognition of glycans by F-type lectins and galectins: molecular, structural, and biophysical aspects. Ann. N.Y. Acad. Sci. 1253:E14-E26, 2012.
263. Matarrese, P., Fusco, O., Tinari, N., et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J. Cancer 85:545-554, 2000.
264. Ohannesian, D.W., Lotan, D., Thomas, P., et al. Carci-noembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res. 55:2191-2199, 1995.
265. Nangia-Makker, P., Raz, T., Tait, L., Hogan, V., Fridman, R., and Raz, A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res. 67:11760-11768, 2007.
266. Ortega, N., Behonick, D.J., Colnot, C., Cooper, D.N., and Werb, Z. Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation. Mol. Biol. Cell 16:3028-3039, 2005.
267. Wang, Y.G., Kim, S.J., Baek, J.H., Lee, H.W., Jeong, S.Y., and Chun, K.H. Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metallopro-teinase-1 expression. Exp. Mol. Med. 44:387-393, 2012.
268. Kim, S.J., Shin, J.Y., Lee, K.D., et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating pro-tease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6:e25103, 2011.
269. Lin, Y.H., Lin, L.Y., Wu, Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin. Chim. Acta 409:96-99, 2009.
270. Santiago-Gomez, A., Barrasa, J.I., Olmo, N., et al. 4F2hc-silencing impairs tumorigenicity of HeLa cells via modulation of galectin-3 and beta-catenin signaling, and MMP-2 expression. Biochim. Biophys. Acta 1833:2045-2056, 2013.
271. Astorgues-Xerri, L., Riveiro, M.E., Tijeras-Raballand, A., et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat. Rev. 40:307-319, 2014.
272. Fermin Lee, A., Chen, H.Y., Wan, L., et al. Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines. Am. J. Pathol. 183:1209-1222, 2013.
273. Alge, C.S., Priglinger, S.G., Kook, D., et al. Galectin-1 influences migration of retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 47:415-426, 2006.
274. Canning, P., Glenn, J.V., Hsu, D.K., Liu, F.T., Gardiner, T.A., and Stitt, A.W. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007:51837, 2007.
275. Fukushima, A., Sumi, T., Fukuda, K., etal. Rolesofgalectin-9 in the development of experimental allergic conjunctivitis in mice. Int. Arch. Allergy Immunol. 146:36-43, 2008.
276. Wang, Z., Handa, J.T., Green, W.R., Stark, W.J., Wein-berg, R.S., and Jun, A.S. Advanced glycation end products and receptors in fuchs' dystrophy corneas undergoing descemet's stripping with endothelial keratoplasty. Ophthalmology 114:1453-1460, 2007.
277. Jin, Q.H., Lou, Y.F., Li, T.L., Chen, H.H., Liu, Q., and He, X.J. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin. Med. J. (Engl) 126:2109-2115, 2013.
278. Shimmura-Tomita, M., Wang, M., Taniguchi, H., Akiba, H., Yagita, H., and Hori, J. Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts. PLoS One 8:e63620, 2013.
279. Argueso, P. Glycobiology of the ocular surface: mucins and lectins. Jpn. J. Ophthalmol. 57:150-155, 2013.
280. Saravanan, C., Cao, Z., Head, S.R., and Panjwani, N. Detection of differentially expressed wound-healing-related glycogenes in galectin-3-deficient mice. Invest. Ophthal-mol. Vis. Sci. 50:5690-5696, 2009.
281. Suryawanshi, A., Cao, Z., Thitiprasert, T., Zaidi, T.S., and Panjwani, N. Galectin-1-mediated suppression of pseu-domonas aeruginosa-induced corneal immunopathology. J. Immunol. 190:6397-6409, 2013.
282. Rajasagi, N.K., Suryawanshi, A., Sehrawat, S., et al. Galectin-1 reduces the severity of herpes simplex virus-induced ocular immunopathological lesions. J. Immunol. 188:4631-4643, 2012.
283. J Reddy, P.B., Schreiber, T.H., Rajasagi, N.K., et al. TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoin-flammatory lesions. J. Virol. 86:10606-10620, 2012.
284. Dahm, R., Bramke, S., Dawczynski, J., Nagaraj, R.H., and Kasper, M. Developmental aspects of galectin-3 expression in the lens. Histochem. Cell Biol. 119:219-226, 2003.
285. Ogden, A.T., Nunes, I., Ko, K., et al. GRIFIN, a novel lens-specific protein related to the galectin family. J. Biol. Chem. 273:28889-28896, 1998.
286. Barton, K.A., Hsu, C.D., and Petrash, J.M. Interactions between small heat shock protein alpha-crystallin and galectin-related interfiber protein (GRIFIN) in the ocular lens. Biochemistry 48:3956-3966, 2009.
287. Goel, R., Murthy, K.R., Srikanth, S.M., et al. Characterizing the normal proteome of human ciliary body. Clin. Proteomics 10:9, 2013.
288. Nguyen, J.V., Soto, I., Kim, K.Y., et al. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc. Natl. Acad. Sci. U.S.A. 108:1176-1181, 2011.
289. Tezel, G., Yang, X., Luo, C., et al. Oxidative stress and the regulation of complement activation in human glaucoma. Invest. Ophthalmol. Vis. Sci. 51:5071-5082, 2010.
290. Fautsch, M.P., Silva, A.O., and Johnson, D.H. Carbohydrate binding proteins galectin-1 and galectin-3 in human trabecular meshwork. Exp. Eye Res. 77:11-16, 2003.
291. Diskin, S., Cao, Z., Leffler, H., and Panjwani, N. The role of integrin glycosylation in galectin-8-mediated trabecular meshwork cell adhesion and spreading. Glycobiology 19:29-37, 2009.
292. Diskin, S., Chen, W.S., Cao, Z., et al. Galectin-8 promotes cytoskeletal rearrangement in trabecular meshwork cells through activation of rho signaling. PLoS One 7:e44400, 2012.
293. Colnot, C., Ripoche, M.A., Milon, G., Montagutelli, X., Crocker, P.R., and Poirier, F. Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 94:290-296, 1998.